

Freedom of Information Act 2000 - Request Reference Fol/21/207

Dermatology & Gastroenterology Drugs

1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 11
- Adalimumab Biosimilar 120
- Apremilast *
- Brodalumab 8
- Certolizumab *
- Dimethyl fumarate *
- Etanercept – Enbrel 0
- Etanercept Biosimilar *
- Guselkumab 10
- Infliximab – Remicade 0
- Infliximab Biosimilar 15
- Ixekizumab 17
- Risankizumab 12
- Secukinumab 15
- Tildrakizumab 0
- Ustekinumab 47

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information above has been replaced with an asterisk. Cardiff and Vale University Health Board will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

There have been no under 16 patients treated with these drugs.

3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira *
- Adalimumab Biosimilar 222
- Golimumab *
- Infliximab – Remicade 0
- Infliximab Biosimilar 107
- Tofacitinib 7
- Ustekinumab 73
- Vedolizumab 15

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information above has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.